KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
10 Jan 2022
New results from immunotherapy trials from the EORTC gynaecological and lung cancer groups presented at ESMO 2021
20 Sep 2021
PRESS RELEASE: First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study
20 Jan 2021
New Data Gives Hope to Small Cell Lung Cancer Patients
18 Sep 2020
Quality of life in lung cancer – EORTC brings the measurements up to date
24 Mar 2020
PRESS RELEASE: Inivata and the European Organisation for Research and Treatment of Cancer (EORTC) collaborate in Phase II NSCLC study
29 Oct 2019
EORTC brings together experts from medical societies to compile a consensus definition for synchronous oligometastatic non small cell lung cancer
18 Sep 2019
The final analysis of SPLENDOUR trial did not show improvement in overall survival in advanced Non-Small Lung Cancer
21 Oct 2018